Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Jay Anders
Fostering Safe AI Use: Jay Anders from Medicomp in a Riveting Conversation with PharmaShots
Shots: Nearly half of FDA-approved AI medical devices lack testing on real patient data, raising significant concerns about patient safety. PharmaShots welcomes Jay Anders, CMO of Medicomp Systems, to discuss AI implementation trends in healthcare and strategies for ethical AI adoption by healthcare professionals. Jay emphasizes the importance of clinical validations to ensure the safe…
December 23, 2024
Viewpoints_Mark Genovese 
Lilly at UEGW 2024: Mark Genovese in an Illuminating Dialogue Exchange with PharmaShots shares insights into VIVID-1 study
Shots: Recently, at UEGW 2024, Lilly presented histologic and combined histologic-endoscopic outcomes from the VIVID-1 Phase III study, which evaluated the safety and efficacy of mirikizumab in adults with moderately to severely active Crohn’s disease A key finding reported during UEG Week highlighted the interactions between mirikizumab and ustekinumab, particularly regarding histologic response and remission,…
December 18, 2024
Viewpoints_Harmony Garges
ViiV at IDWeek 2024: Dr. Harmony Garges in an Illuminating Dialogue Exchange with PharmaShots
Shots: Recently at IDWeek 2024, ViiV Healthcare presented data from two real-world studies on Apretude, a long-acting injectable (LAI) for HIV pre-exposure prophylaxis. Dr. Harmony Garges, Chief Medical Officer at ViiV, shared insights from the presentations. The Opera cohort study found Apretude to be 99.7% effective in preventing HIV among participants. Additionally, the Trio Health…
December 16, 2024
Viewpoints_Dino Kazanis_James C. Swartz
Inspiring Innovations: Dino Kazanis and James Swartz in a Stimulating Conversation with PharmaShots
Shots: Thermo Fisher Scientific has recently signed a distribution agreement with Labguru to accelerate research and drive scientific breakthroughs. This collaboration integrates Labguru’s state-of-the-art Electronic Lab Notebook (ELN) with Thermo Fisher Scientific’s comprehensive suite of Laboratory Information Management Systems (LIMS) and lab operations software solutions. By combining ELN and LIMS tools, the partnership aims to…
December 11, 2024
Viewpoints_Marcelo Freire
Takeda at UEG Week 2024: Marcelo Freire from Takeda in an Enlightening Conversation with PharmaShots
Shots: Recently, Takeda shared 32-week interim results from the VERDICT study, which evaluated Entyvio (vedolizumab) for the treatment of patients with ulcerative colitis (UC) Entyvio achieved a stringent endpoint of disease clearance, a new concept in UC clinical research, which is a combination of clinical, endoscopic, and histologic remission Today at PharmaShots, we are joined…
December 2, 2024
Viewpoints_Richard Watts
Enhancing Diagnostic Care: Richard Watts from Qiagen in a Stimulating Conversation with PharmaShots
Shots: Recently, Qiagen entered into a collaboration agreement with AstraZeneca to develop companion diagnostics for chronic diseases using Qiagen’s QIAstat-Dx system Today, at PharmaShots, we are joined by Richard Watts from Qiagen, who sheds light on their collaboration agreements with AstraZeneca and Eli Lilly, leveraging their syndromic testing platform, QIAstat-Dx Qiagen has partnered with over…
November 27, 2024
Viewpoints_John Santini
Fluorescence Visualization in Lung Cancer: John Santini from Vergent Bioscience in Conversation with PharmaShots
Shots: With the growing significance of minimally invasive surgery comes the need for enhanced visualization to optimize surgical outcomes for both surgeons and patients. Vergent BioScience’s VGT-309 shows promising potential for tumor visualization during lung cancer surgeries. VGT-309 is an investigational intraoperative molecular imaging (IMI) agent that utilizes near-infrared (NIR) fluorescence imaging to improve precision. …
November 25, 2024
Viewpoints_Samuel Gidding_Allison Jamison
Bringing Awareness to the Public: Samuel S. Gidding & Allison Jamison in an Enlightening Conversation with PharmaShots
Shots: Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic condition that affects approximately 1 in 250,000 Americans. It is characterized by the presence of two genetic mutations that lead to extremely high levels of LDL cholesterol. In this interview, Sam Gidding and Allison Jamison from the Family Heart Foundation/ emphasize the critical need for enhanced…
November 18, 2024
Load more